Effect of high-dose intravenous immunoglobulin on anti-HLA antibodies in sensitized kidney transplant candidates

Clinical Transplantation

Volumn 26, Issue 3, 2012, Pages

  Nair, Vinay ^a   Sawinski, Deirdre ^b   Akalin, Enver ^c   Friedlander, Rex ^d   Ebcioglu, Zeynep ^a   Sehgal, Vinita ^a   Dinavahi, Rajani ^a   Khaim, Rafael ^a   Ames, Scott ^a   Lerner, Susan ^a   Murphy, Barbara ^a   Bromberg, Jonathan S ^e   Heeger, Peter S ^a   Schröppel, Bernd ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d ROGOSIN INSTITUTE   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Desensitization; Intravenous immunoglobulin; Kidney transplantation; Panel reactive antibody; Sensitization

Indexed keywords

HLA ANTIBODY; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; PANEL REACTIVE ANTIBODY;

ADOLESCENT; ADULT; AGED; ANTIGEN ANTIBODY REACTION; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL PRACTICE; CLINICAL PROTOCOL; DESENSITIZATION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; GRAFT RECIPIENT; HUMAN; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; CHILD; DESENSITIZATION, IMMUNOLOGIC; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HLA ANTIGENS; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; WAITING LISTS;

EID: 84862258442     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2012.01657.x     Document Type: Article

References (22)

1. OPTN/SRTR Annual Report: Transplant Data 1999-2008. Accessed April 4, 2011.
2. Amico P, Honger G, Mayr M, Steiger J, Hopfer H, Schaub S. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation 2009: 87: 1681.
3. Riethmuller S, Ferrari-Lacraz S, Muller MK et al. Donor-specific antibody levels and three generations of crossmatches to predict antibody-mediated rejection in kidney transplantation. Transplantation 2010: 90: 160.
4. Opelz G. Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. Lancet 2005: 365: 1570.
5. Tait BD, Hudson F, Cantwell L et al. Review article: luminex technology for HLA antibody detection in organ transplantation. Nephrology (Carlton) 2009: 14: 247.
6. Tinckam K. Histocompatibility methods. Transplant Rev (Orlando) 2009: 23: 80.
7. Lefaucheur C, Suberbielle-Boissel C, Hill GS et al. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Am J Transplant 2008: 8: 324.
8. Akalin E, Dinavahi R, Friedlander R et al. Addition of plasmapheresis decreases the incidence of acute antibody-mediated rejection in sensitized patients with strong donor-specific antibodies. Clin J Am Soc Nephrol 2008: 3: 1160.
9. Zachary AA, Sholander JT, Houp JA, Leffell MS. Using real data for a virtual crossmatch. Hum Immunol 2009: 70: 574.
10. Jordan SC, Tyan D, Stablein D et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 2004: 15: 3256.
11. Vo AA, Lukovsky M, Toyoda M et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008: 359: 242.
12. Stegall MD, Gloor J, Winters JL, Moore SB, Degoey S. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006: 6: 346.
13. Vo AA, Peng A, Toyoda M et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 2010: 89: 1095.
14. Murphy KM, Travers P, Walport M. Janeway's Immunobiology, 7th edn. New York, NY: Garland Science Publishing, 2008.
15. Ferrari-Lacraz S, Aubert V, Buhler L et al. Anti-HLA antibody repertoire after IVIg infusion in highly sensitized patients waiting for kidney transplantation. Swiss Med Wkly 2006: 136: 696.
16. Reinsmoen NL, Lai CH, Vo A et al. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation 2008: 86: 820.
17. Jordan SC, Toyoda M, Vo AA. Intravenous immunoglobulin a natural regulator of immunity and inflammation. Transplantation 2009: 88: 1.
18. Wassmuth R, Hauser IA, Schuler K et al. Differential inhibitory effects of intravenous immunoglobulin preparations on HLA-alloantibodies in vitro. Transplantation 2001: 71: 1436.
19. Arumugam TV, Tang SC, Lathia JD et al. Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death. Proc Natl Acad Sci U S A 2007: 104: 14104.
20. Glotz D, Haymann JP, Sansonetti N et al. Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIg). A potential tool for transplantation of immunized patients. Transplantation 1993: 56: 335.
21. Basta M. Ambivalent effect of immunoglobulins on the complement system: activation versus inhibition. Mol Immunol 2008: 45: 4073.
22. Bonilla FA. Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes. Immunol Allergy Clin North Am 2008: 28: 803.